|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Variable Interest Entity, Primary Beneficiary | ||||||||||||||||||||
| Total restricted cash | ||||||||||||||||||||
| Other short-term investments | ||||||||||||||||||||
| Investment securities (includes available-for-sale securities of $14,502 and $14,359 reported at fair value with associated amortized cost of $14,489 and $14,475 at March 31, 2025 and December 31, 2024, respectively) | ||||||||||||||||||||
| Loan receivables | ||||||||||||||||||||
| Financing Receivable, Held-for-Sale | ||||||||||||||||||||
| Variable Interest Entity, Primary Beneficiary | ||||||||||||||||||||
| Total financing Receivable, Held-for-Sale | ||||||||||||||||||||
| Loan Portfolio, excluding held for sale | ||||||||||||||||||||
| Variable Interest Entity, Primary Beneficiary | ||||||||||||||||||||
| Total loan Portfolio, excluding held for sale | ||||||||||||||||||||
| Variable Interest Entity, Primary Beneficiary | ||||||||||||||||||||
| Total loan receivables | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Variable Interest Entity, Primary Beneficiary | ||||||||||||||||||||
| Total allowance for credit losses | ||||||||||||||||||||
| Net loan receivables | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Variable Interest Entity, Primary Beneficiary | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Interest-bearing deposit accounts | ||||||||||||||||||||
| Non-interest bearing deposit accounts | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Long-term borrowings | ||||||||||||||||||||
| Variable Interest Entity, Primary Beneficiary | ||||||||||||||||||||
| Total long-term borrowings | ||||||||||||||||||||
| Short- and long-term borrowings | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Variable Interest Entity, Primary Beneficiary | ||||||||||||||||||||
| Total accrued expenses and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' Equity | ||||||||||||||||||||
| Common stock, par value $0.01 per share; 2,000,000,000 shares authorized; 573,042,256 and 572,608,227 shares issued at March 31, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Preferred stock, par value $0.01 per share; 200,000,000 shares authorized; 10,700 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost; 321,413,252 and 321,268,743 shares at March 31, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
